Revolution Medicines Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-1.13B | $-600.1M | $-436.4M | $-248.7M | $-187.1M | $-108.2M | $-47.7M | $-41.8M |
| Depreciation & Amortization | $7.8M | $6.6M | $5.0M | $4.0M | $3.1M | $2.6M | $2.3M | $1.6M |
| Depreciation | $7.4M | $6.2M | $5.0M | $4.0M | $3.1M | — | — | — |
| Amortization | $870.0K | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $198.0K |
| Stock-Based Compensation | $118.4M | $79.2M | $61.8M | $31.2M | $20.7M | $8.9M | $3.2M | $855.0K |
| Net Cash from Operating Activities | $-897.7M | $-557.4M | $-350.6M | $-224.4M | $-147.2M | $-100.1M | $-49.6M | $1.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $16.0M | $10.3M | $7.7M | $10.8M | $6.5M | $2.9M | $2.6M | $1.5M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $118.1M | $-554.4M | $-342.6M | $-24.1M | $-142.1M | $-234.2M | $-102.0M | $-1.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | $0 | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $621.5M | $959.4M | $1.23B | $301.4M | $294.2M | $422.8M | $98.7M | $60.8M |
| Net Change in Cash | $-158.2M | $-152.4M | $536.0M | $52.9M | $4.9M | $88.5M | $-52.9M | $60.7M |
| Free Cash Flow | $-913.7M | $-567.7M | $-358.3M | $-235.2M | $-153.7M | $-103.0M | $-52.2M | $-286.0K |